Opexa Therapeutics Reports Second Quarter 2012 Financial Results and Provides Corporate Update

Published: Aug 13, 2012

THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tcelnaâ„¢, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended June 30, 2012 and provided an overview of recent corporate developments.

Back to news